4D Molecular Therapeutics' Q3 revenue misses

4D Molecular Therapeutics

10/11/2025 13:10

Overview

4D Molecular Therapeutics Q3 revenue missed analyst expectations

Net income for Q3 missed analyst estimates

Company entered strategic partnership with Otsuka, receiving $85 mln upfront cash

Outlook

4DMT expects cash runway into 2H 2028, supported by Otsuka partnership and equity offering

4DMT expects interim data from AEROW Phase 1 trial by year-end 2025

Result Drivers

Research and development expenses were $49.4 million for the third quarter of 2025, as compared to $38.5 million for the third quarter of 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$90,000
$287,900 (7 Analysts)
Q3 Net Income
Miss
-$56.88 mln
-$56.20 mln (4 Analysts)
Q3 Operating Income
Slight Beat*
-$61.19 mln
-$61.60 mln (5 Analysts)
Q3 Basic EPS
-$1.01
Q3 Operating Expenses
$61.28 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $34.50, about 69.6% above its November 7 closing price of $10.50

Press Release: ID:nGNX5qGQ2W

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)